Miguel Castelo-Branco Selected Research

Miguel Castelo-Branco Research Topics

Disease

12	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 01/2016
9	Autism Spectrum Disorder 05/2022 - 01/2018
8	Stroke (Strokes) 01/2022 - 01/2014
8	Type 2 Diabetes Mellitus (MODY) 08/2021 - 06/2014
7	Autistic Disorder (Autism) 05/2022 - 01/2017
7	Parkinson Disease (Parkinson's Disease) 01/2021 - 04/2015
5	Neuroinflammatory Diseases 01/2021 - 01/2019
5	Cognitive Dysfunction 01/2021 - 01/2016
4	Machado-Joseph Disease (Spinocerebellar Ataxia Type 3) 01/2022 - 10/2016
4	Calcinosis 01/2022 - 01/2017
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 11/2022 - 11/2014
3	Atherosclerotic Plaque (Atheroma) 01/2022 - 01/2017
3	Atrophy 01/2021 - 12/2018
3	Dementia (Dementias) 01/2019 - 01/2016
3	Motor Disorders 01/2017 - 01/2011
3	Neurofibromatosis 1 (Neurofibromatosis Type I) 08/2016 - 03/2013
3	Hypertension (High Blood Pressure) 01/2011 - 10/2010
2	Neurodevelopmental Disorders 05/2022 - 01/2017
2	Schizophrenia (Dementia Praecox) 05/2022 - 01/2020
2	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 05/2022 - 12/2015
2	Ganglion Cysts (Ganglion) 01/2021 - 01/2013
2	Neoplasms (Cancer) 10/2020 - 02/2014
2	Pancreatitis 06/2020 - 01/2020
2	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 01/2020 - 01/2018
2	Optic Nerve Diseases (Optic Neuropathy) 12/2018 - 10/2016
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 05/2018 - 02/2011
2	Glucose Intolerance 01/2018 - 10/2017
2	Amyloid Plaque 01/2018 - 01/2018
2	Obesity 10/2017 - 01/2017
2	Glaucoma 07/2015 - 02/2004
2	Cataract (Cataracts) 11/2013 - 01/2013
2	Essential Hypertension 02/2011 - 01/2011
2	Disease Progression 12/2008 - 02/2004
1	Demyelinating Diseases (Demyelinating Disease) 07/2022
1	Multiple Sclerosis 07/2022
1	COVID-19 10/2021
1	Parkinsonian Disorders (Parkinsonism) 01/2021
1	Glioblastoma (Glioblastoma Multiforme) 10/2020
1	Aortic Valve Stenosis (Aortic Stenosis) 08/2020
1	Antisocial Personality Disorder (Antisocial Personality) 01/2020
1	Nervous System Diseases (Neurological Disorders) 01/2020
1	Brain Diseases (Brain Disorder) 01/2020
1	Substance-Related Disorders (Drug Abuse) 01/2020
1	Animal Disease Models 01/2020
1	Pain (Aches) 01/2020
1	Bipolar Disorder (Manic Depressive Psychosis) 01/2020
1	Psychotic Disorders (Schizoaffective Disorder) 01/2020
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2020
1	Left Ventricular Dysfunction 01/2020
1	Critical Illness (Critically Ill) 01/2019

Drug/Important Bio-Agent (IBA)

19	Retinaldehyde (Retinal)IBA 01/2022 - 03/2008
19	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2004
7	gamma-Aminobutyric Acid (GABA)IBA 01/2020 - 03/2013
7	2- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- oneIBA 01/2020 - 01/2011
5	Amyloid (Amyloid Fibrils)IBA 01/2021 - 01/2016
5	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 01/2021 - 01/2016
5	Antihypertensive Agents (Antihypertensives)IBA 01/2019 - 10/2010
3	Sodium Fluoride (Ossin)FDA Link 01/2022 - 02/2020
3	Glutamic Acid (Glutamate)FDA Link 01/2020 - 01/2018
3	Indicators and Reagents (Reagents)IBA 01/2018 - 02/2014
3	Aminobutyrates (Aminobutyric Acid)IBA 01/2017 - 03/2013
2	Pharmaceutical PreparationsIBA 10/2020 - 01/2011
2	FluoridesIBA 08/2020 - 01/2017
2	polyglutamineIBA 01/2020 - 01/2018
2	Ataxin-3IBA 01/2020 - 01/2018
2	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 10/2017
2	ImmunosorbentsIBA 01/2019 - 01/2016
2	EnzymesIBA 01/2019 - 01/2016
2	LeptinIBA 01/2019 - 10/2017
2	N-acetylaspartate (N-acetyl aspartate)IBA 01/2018 - 01/2018
2	2- carbomethoxy- 8- (3- fluoropropyl)- 3- (4- iodophenyl)tropaneIBA 01/2018 - 04/2015
2	CalciumIBA 01/2017 - 06/2014
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 11/2022
1	CopperIBA 07/2022
1	CuprizoneIBA 07/2022
1	Chelating AgentsIBA 07/2022
1	W 7 (W7)IBA 07/2022
1	Fluorine-18IBA 01/2022
1	AntioxidantsIBA 08/2021
1	TEMPOIBA 04/2021
1	salicylhydroxamic acid (SHAM)IBA 04/2021
1	Biological ProductsIBA 01/2021
1	RacloprideIBA 01/2021
1	Peptides (Polypeptides)IBA 10/2020
1	LipidsIBA 10/2020
1	4-aminospiroperidolIBA 01/2020
1	Protons (Proton)IBA 01/2020
1	Inositol (Myoinositol)IBA 01/2020
1	(R)- (11C)1- (2- chlorophenyl)- N- methyl- N- (1- methylpropyl)- 3- isoquinolinecarboxamideIBA 01/2020
1	Mitochondrial Proteins (Mitochondrial Protein)IBA 01/2020
1	Fibrinogen (Factor I)FDA Link 01/2020
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2020

Therapy/Procedure

6	Brain-Computer Interfaces 01/2022 - 01/2011
5	Therapeutics 05/2022 - 12/2010
5	Neurofeedback 01/2020 - 12/2015
4	Transcranial Magnetic Stimulation 01/2022 - 01/2018
4	Neurological Rehabilitation 01/2021 - 01/2014
3	Transcranial Direct Current Stimulation 05/2022 - 01/2020
1	Continuity of Patient Care 10/2021
1	Secondary Prevention 01/2020